MetLife Investment Management LLC Has $924,000 Stock Holdings in Teladoc Health, Inc. (NYSE:TDOC)

MetLife Investment Management LLC lifted its position in Teladoc Health, Inc. (NYSE:TDOC) by 3.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 101,612 shares of the health services provider’s stock after buying an additional 3,108 shares during the quarter. MetLife Investment Management LLC’s holdings in Teladoc Health were worth $924,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also modified their holdings of the company. Versant Capital Management Inc lifted its position in Teladoc Health by 313.8% during the 4th quarter. Versant Capital Management Inc now owns 3,219 shares of the health services provider’s stock worth $29,000 after acquiring an additional 2,441 shares during the last quarter. Whipplewood Advisors LLC acquired a new position in shares of Teladoc Health during the 4th quarter worth about $29,000. Lindbrook Capital LLC boosted its stake in Teladoc Health by 78.9% during the 4th quarter. Lindbrook Capital LLC now owns 3,654 shares of the health services provider’s stock valued at $33,000 after purchasing an additional 1,612 shares during the period. Sterling Capital Management LLC grew its holdings in Teladoc Health by 776.7% in the 4th quarter. Sterling Capital Management LLC now owns 4,629 shares of the health services provider’s stock valued at $42,000 after buying an additional 4,101 shares during the last quarter. Finally, Pilgrim Partners Asia Pte Ltd bought a new position in Teladoc Health in the 4th quarter worth approximately $60,000. 76.82% of the stock is owned by institutional investors.

Teladoc Health Price Performance

Shares of Teladoc Health stock opened at $7.07 on Friday. The stock has a market capitalization of $1.24 billion, a price-to-earnings ratio of -1.23 and a beta of 1.73. The firm’s 50-day moving average price is $8.02 and its two-hundred day moving average price is $9.49. The company has a current ratio of 1.73, a quick ratio of 1.69 and a debt-to-equity ratio of 0.66. Teladoc Health, Inc. has a 1-year low of $6.35 and a 1-year high of $15.21.

Teladoc Health (NYSE:TDOC) last released its quarterly earnings results on Wednesday, February 26th. The health services provider reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.07). The business had revenue of $640.49 million for the quarter, compared to analyst estimates of $639.44 million. Teladoc Health had a negative net margin of 37.91% and a negative return on equity of 10.06%. On average, equities analysts predict that Teladoc Health, Inc. will post -1.16 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Teladoc Health news, insider Adam C. Vandervoort sold 11,011 shares of the company’s stock in a transaction on Thursday, March 20th. The stock was sold at an average price of $8.42, for a total transaction of $92,712.62. Following the transaction, the insider now owns 64,308 shares of the company’s stock, valued at approximately $541,473.36. This represents a 14.62 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.58% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the company. Bank of America reduced their price objective on Teladoc Health from $9.50 to $8.00 and set a “neutral” rating for the company in a research report on Friday, April 11th. Royal Bank of Canada increased their price target on shares of Teladoc Health from $11.00 to $12.00 and gave the company an “outperform” rating in a report on Friday, January 24th. Evercore ISI dropped their price objective on shares of Teladoc Health from $8.00 to $7.00 and set an “in-line” rating on the stock in a report on Thursday. Oppenheimer decreased their target price on Teladoc Health from $14.00 to $12.00 and set an “outperform” rating on the stock in a research report on Friday, January 24th. Finally, Piper Sandler cut their price target on Teladoc Health from $13.00 to $12.00 and set an “overweight” rating for the company in a report on Thursday, February 27th. Eleven equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $9.81.

Teladoc Health Company Profile

Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.